| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC20A3 |
| Uniprot No | P53007 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 47-87aa |
| 氨基酸序列 | EYVKTQLQLDERSHPPRYRGIGDCVRQTVRSHGVLGLYRGL |
| 预测分子量 | 31.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SLC20A3重组蛋白的参考文献示例(内容为模拟，建议通过学术数据库核实)：
1. **《Functional characterization of SLC20A3 mutations in familial idiopathic basal ganglia calcification》**
- 作者：Jensen, N., et al.
- 摘要：通过重组表达SLC20A3突变体于HEK293细胞，研究其磷酸盐转运功能缺失与脑钙化疾病的关联，发现特定突变导致蛋白定位异常及转运活性下降。
2. **《Recombinant SLC20A3 expression and phosphate transport in mammalian cells》**
- 作者：Leyva, A., et al.
- 摘要：在哺乳动物细胞中重组表达SLC20A3蛋白，证实其作为钠依赖性磷酸盐共转运体的功能，并分析其动力学参数及调控机制。
3. **《pH-dependent phosphate transport by recombinant SLC20A3 in Xenopus oocytes》**
- 作者：Bøttger, P., & Hammershaimb, M.
- 摘要：利用非洲爪蟾卵母细胞表达重组SLC20A3.揭示其磷酸盐转运活性对pH的敏感性，提出其在酸碱平衡中的潜在作用。
4. **《Structural insights into SLC20A3-mediated phosphate homeostasis》**
- 作者：Bibert, S., et al.
- 摘要：通过重组蛋白纯化及结构模拟，解析SLC20A3的跨膜结构域，探讨其与磷酸盐结合及转运的分子机制。
建议通过PubMed或Google Scholar检索最新文献，以获取准确信息。
**Background of SLC20A3 Recombinant Protein**
The solute carrier family 20 member 3 (SLC20A3) gene encodes a sodium-dependent phosphate transporter, PiT2. which plays a critical role in cellular phosphate homeostasis. SLC20A3 belongs to the SLC20 transporter family, alongside SLC20A1 (PiT1), both of which facilitate the uptake of inorganic phosphate (Pi) across cell membranes. Phosphate is essential for numerous biological processes, including energy metabolism (e.g., ATP synthesis), signal transduction, and bone mineralization. Dysregulation of phosphate transport has been implicated in pathological conditions such as vascular calcification, kidney dysfunction, and neurodegenerative disorders like primary familial brain calcification (PFBC), where SLC20A3 mutations are frequently observed.
Recombinant SLC20A3 protein is produced using biotechnological methods, often through heterologous expression systems like mammalian cells (e.g., HEK293) or insect cells (e.g., Sf9), ensuring proper post-translational modifications and functional activity. The recombinant protein retains the structural and transport properties of native PiT2. enabling researchers to study its kinetics, substrate specificity, and regulatory mechanisms in vitro. Its production typically involves cloning the SLC20A3 cDNA into expression vectors, followed by purification via affinity chromatography (e.g., His-tag or FLAG-tag systems).
Studies utilizing SLC20A3 recombinant protein have advanced understanding of its role in phosphate signaling and disease. For instance, it has been employed to investigate how specific mutations (e.g., T64M, V147M) disrupt phosphate transport, contributing to PFBC pathogenesis. Additionally, recombinant SLC20A3 serves as a tool for drug screening to identify modulators of phosphate transport, potentially offering therapeutic strategies for calcification-related disorders. Its application extends to structural biology, aiding in resolving 3D conformations and interaction sites through techniques like cryo-EM or X-ray crystallography. Overall, SLC20A3 recombinant protein is a vital resource for dissecting phosphate metabolism and its links to human diseases.
×
